|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Kyowa_Kirin
gptkb:ribociclib
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:letrozole
gptkb:anastrozole
|
|
gptkbp:class
|
CD K4/6 inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
MONALEESA-1
MONALEESA-2
MONALEESA-3
MONALEESA-7
|
|
gptkbp:contraindication
|
hypersensitivity
QT prolongation
liver impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
as prescribed by physician
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
400 mg
200 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kisqali
|
|
gptkbp:ingredients
|
gptkb:ribociclib
|
|
gptkbp:interacts_with
|
antibiotics
anticoagulants
antifungals
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
|
|
gptkbp:is_monitored_by
|
electrocardiogram
liver function tests
complete blood count
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:market
|
available by prescription
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
metabolized by CY P3 A4
|
|
gptkbp:population
|
postmenopausal women
HE R2-negative
hormone receptor-positive
|
|
gptkbp:requires
|
available online
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
vomiting
diarrhea
hair loss
neutropenia
|
|
gptkbp:storage
|
room temperature
protected from light
protected from moisture
|
|
gptkbp:type_of_care
|
important for efficacy
|